VRTX250117P170000
- 1.05
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio With Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
BMO Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $520
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $441
Barclays Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $418
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $418 to $575
Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals: Balancing Growth Prospects and Uncertainties With a Hold Rating
Vertex Pharmaceuticals: Strong Future Potential With Key Drug Launches and Underappreciated Opportunities
Stifel Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $494
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Vertex Pharmaceuticals (VRTX)
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
Citi Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
Reported Earlier, Vertex Unveils Comprehensive Updates On CF, SCD, And Pipeline Progress Across Multiple Disease Areas For 2025
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Vertex Pharmaceuticals (VRTX) Stock Moves -0.62%: What You Should Know
Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals
Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
Vertex Pharmaceuticals Analyst Ratings
Vertex Pharmaceuticals Incorporated (VRTX) Slid Due to Setbacks In Clinical Trials